PsyMuKB

Gene-drug interactions (data source: DGIdb)

Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
CYP2B6	1555	TAMOXIFEN	CHEMBL83		PharmGKB
CYP2B6	1555	COLCHICINE	CHEMBL107		NCI	12815172
CYP2B6	1555	CLOPIDOGREL	CHEMBL1771		PharmGKB
CYP2B6	1555	DIAZEPAM	CHEMBL12		PharmGKB
CYP2B6	1555	AFLATOXIN	CHEMBL1697694		PharmGKB
CYP2B6	1555	THIOTEPA	CHEMBL671		PharmGKB
CYP2B6	1555	ARTEMISININ	CHEMBL567597		PharmGKB
CYP2B6	1555	MEPHENYTOIN	CHEMBL861		PharmGKB
CYP2B6	1555	STAVUDINE	CHEMBL991		PharmGKB
CYP2B6	1555	METHYLENEDIOXYMETHAMPHETAMINE	CHEMBL43048		PharmGKB
CYP2B6	1555	ETHINYL ESTRADIOL	CHEMBL691		PharmGKB
CYP2B6	1555	PRASUGREL	CHEMBL1201772		FDA
CYP2B6	1555	MEPERIDINE	CHEMBL607		PharmGKB
CYP2B6	1555	SELEGILINE	CHEMBL972		PharmGKB
CYP2B6	1555	MIDAZOLAM	CHEMBL655		PharmGKB
CYP2B6	1555	BUPROPION	CHEMBL894		PharmGKB
CYP2B6	1555	BIFONAZOLE	CHEMBL277535		DrugBank	10592235
CYP2B6	1555	CHEMBL1235146	CHEMBL1235146		DrugBank	10592235
CYP2B6	1555	TROFOSFAMIDE	CHEMBL462019		NCI	10447581
CYP2B6	1555	IFOSFAMIDE	CHEMBL1024		PharmGKB
CYP2B6	1555	TICLOPIDINE	CHEMBL833	inhibitor	GuideToPharmacologyInteractions
CYP2B6	1555	BICALUTAMIDE	CHEMBL409		NCI	9622849
CYP2B6	1555	LAMIVUDINE	CHEMBL141		PharmGKB
CYP2B6	1555	CARBAMAZEPINE	CHEMBL108		PharmGKB, NCI	14977870
CYP2B6	1555	EFAVIRENZ	CHEMBL223228		NCI, FDA	17041008
CYP2B6	1555	6-O-BENZYLGUANINE	CHEMBL407874		NCI	7503788
CYP2B6	1555	PHENOBARBITAL	CHEMBL40		PharmGKB, NCI	14977870
CYP2B6	1555	RITONAVIR	CHEMBL163		NCI	14977870
CYP2B6	1555	CYCLOPHOSPHAMIDE	CHEMBL88		PharmGKB, NCI	15228172, 15746054, 15919850, 8242617
CYP2B6	1555	TESTOSTERONE	CHEMBL386630		NCI	10630892
CYP2B6	1555	NEVIRAPINE	CHEMBL57		NCI	17041008

Variant-drug associations (data source: PharmGKB)

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CYP2B6	CYP2B61, CYP2B66	6/6		metabolism/PK	no	No details about which specific variants/alleles were tested for, however the authors state that genotyping of 1/6 individuals did not exclude the possibility of them actually being 4/9.	CYP2B6 6/6 is associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to CYP2B6 1/1.	21589866	1451161580
CYP2B6	CYP2B61, CYP2B64, CYP2B6*6	1/4 + 1/6 + 4/6 + 6/6	methadone	efficacy	no	No significant difference in genotype or phenotype frequencies between responders and non-responders, as defined by drug misuse during methadone maintenance therapy. No details about which specific variants/alleles were tested for, however the authors state that genotyping of 1/6 individuals did not exclude the possibility of them actually being 4/9.	CYP2B6 1/4 + 1/6 + 4/6 + 6/6 are not associated with response to methadone in people with Opioid-Related Disorders as compared to CYP2B6 1/1.	21589866	1451161400
CYP2B6	CYP2B61, CYP2B66	6/6	methadone	dosage	no	This association was not significant. No details about which specific variants/alleles were tested for, however the authors state that genotyping of 1/6 individuals did not exclude the possibility of them actually being 4/9.	CYP2B6 6/6 is associated with decreased dose of methadone in people with Opioid-Related Disorders as compared to CYP2B6 1/1.	21589866	1451161493
CYP2B6	CYP2B61, CYP2B65, CYP2B66, CYP2B67	6/6		metabolism/PK	yes	Study in patients receiving methadone maintenance therapy. Patients were genotyped for the 4, 5, 6, 7 and *9 alleles, but no details on the specific variants assayed are given.	CYP2B6 6/6 is associated with increased concentrations of (S)-methadone as compared to CYP2B6 1/1 + 1/5 + 1/6 + 1/7.	17502774	1451156500
CYP2B6	CYP2B61, CYP2B65, CYP2B66, CYP2B67	6/6		metabolism/PK	no	Study in patients receiving methadone maintenance therapy. Patients were genotyped for the 4, 5, 6, 7 and *9 alleles, but no details on the specific variants assayed are given.	CYP2B6 6/6 is not associated with concentrations of (R)-methadone as compared to CYP2B6 1/1 + 1/5 + 1/6 + 1/7.	17502774	1451156540
CYP2B6	CYP2B61, CYP2B65, CYP2B66, CYP2B67	6/6	quetiapine	metabolism/PK	no	Study in patients receiving methadone maintenance therapy. No significant difference in plasma level-dose ratios of quetiapine between genotype groups. Patients were genotyped for the 4, 5, 6, 7 and *9 alleles, but no details on the specific variants assayed are given.	CYP2B6 6/6 is not associated with concentrations of quetiapine as compared to CYP2B6 1/1 + 1/5 + 1/6 + 1/7.	17502774	1451156368
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	Mean log efavirenz trough concentrations increased with the number of T alleles.	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	20952418	1184988306
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	yes	Note: combined analysis with rs3745274 Mean log efavirenz trough concentrations increased with the number of rs3745274 T or rs28399499 C alleles.	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	20952418	1184988315
CYP2B6	CYP2B6*6	6/6	efavirenz	metabolism/PK	yes	Note: combined analysis of loss of function alleles - diplotypes described in the population were n=2 6/6, n=3 1/18 n=2 1/9. Mean log efavirenz trough concentrations increased with the number of loss of function alleles.	CYP2B6 6/6 is associated with decreased metabolism of efavirenz in people with HIV.	20952418	1184988338
CYP2B6	rs2279343	AG	efavirenz	metabolism/PK	yes	As shown by increased plasma concentrations (units = mg/L) for those with the AG genotype compared to those with the AA genotype. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	Genotype AG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AA.	23254426	1183491467
CYP2B6	rs2279343	GG	efavirenz	"dosage","metabolism/PK"	no	Case study of a male who began ART including efavirenz and experienced severe adverse drug events. Later, high efavirenz plasma concentrtaions were observed when he began a TDM program. Efavirenz dose was subsequently reduced twice during the course of treatment (due to high plasma concentrations) and this correlated with a reduction in adverse events. The patient's genotype was CYP2B6 rs3745274 TT and rs2279343 GG.	Genotype GG is associated with decreased dose of efavirenz in men with HIV Infections.	20441246	1184511697
CYP2B6	CYP2B61, CYP2B69	1/9	efavirenz	metabolism/PK	yes	Note: combined analysis of loss of function alleles - diplotypes described in the population were n=2 6/6, n=3 1/18 n=2 1/9. Mean log efavirenz trough concentrations increased with the number of loss of function alleles.	CYP2B6 1/9 is associated with decreased metabolism of efavirenz in people with HIV.	20952418	1184988354
CYP2B6	rs2279343	AG	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the AG genotype compared to patients with the AA genotype.	Genotype AG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	23399569	1184473253
CYP2B6	rs2279343	G	efavirenz	metabolism/PK	yes		Allele G is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele A.	26779253	1447680752
CYP2B6	CYP2B61, CYP2B66	*6	tramadol	metabolism/PK	not stated	No association between the CYP2B66 allele and concentrations of tramadol and its metabolites. Note that the paper does not provide details on how the 6 allele was identified.	CYP2B6 6 is not associated with metabolism of tramadol in people with Neoplasms and Pain as compared to CYP2B6 1.	30051214	1451229760
CYP2B6	rs3745274	TT	efavirenz	"dosage","metabolism/PK"	no	Case study of a male who began ART including efavirenz and experienced severe adverse drug events. Later, high efavirenz plasma concentrtaions were observed when he began a TDM program. Efavirenz dose was subsequently reduced twice during the course of treatment (due to high plasma concentrations) and this correlated with a reduction in adverse events. The patient's genotype was CYP2B6 rs3745274 TT and rs2279343 GG.	Genotype TT is associated with decreased dose of efavirenz in men with HIV Infections.	20441246	1184511673
CYP2B6	rs3745274	GT + TT	nevirapine	"toxicity","metabolism/PK"	not stated	" The impact of 516G > T was tested including heterozygous and homozygous subjects, showing that both genotypes influenced CL/F to a significant extent (ΔOFV = −27.8). Particularly significant was the effect of the 516TT genotype, which decreased CL/F by 37%. Importantly, there was a gene–dose effect with 516GT decreasing CL/F by 15% compared with the 516GG genotype. "	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	21441248	827861835
CYP2B6	rs3745274	GT + TT	nevirapine	metabolism/PK	yes	Those with the GT and TT genotypes had a 7.6% and a 19.5% reduction in clearance of nevirapine, respectively, as compared to those with the GG genotype. This SNP remained in the multiple SNP analysis model after backwards elimination.	Genotypes GT + TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	24217698	1296598965
CYP2B6	rs3745274	GT + TT	nevirapine	"dosage","metabolism/PK"	yes	GT + TT were associated with increased exposure to drug, as measured by increased area under the concentration time curve and decreased apparent oral clearance of the drug. This was not statistically significant after multiple comparison correction, but was significant in a multiple variant model for nevirapine AUC (p=0.0001) [stat_test: linear regression]	Genotypes GT + TT are associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	22111602	827823670
CYP2B6	rs28399499	CT	nevirapine	metabolism/PK	not stated	Those with the CT genotype had a 33% reduction in clearance of nevirapine as compared to those with the TT genotype. This SNP remained in the multiple SNP analysis model after backwards elimination.	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	24217698	1296598953
CYP2B6	rs28399499	CT	nevirapine	"toxicity","metabolism/PK"	not stated	The 983TC genotype decreased clearance of Nevirapine by 40%.	Genotype CT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	21441248	827861853
CYP2B6	CYP2B61, CYP2B66	*6	methadone	dosage	no	The CYP2B6*6 allele was genotyped for using the variants rs3745274 and rs2279343.	CYP2B6 6 is not associated with dose of methadone as compared to CYP2B6 1.	28723731	1451226244
CYP2B6	CYP2B61, CYP2B66	6/6	methadone	metabolism/PK	yes	The CYP2B66 allele was genotyped for using the variants rs3745274 and rs2279343. Individuals with the 6/*6 genotype had significantly increased absolute concentrations and concentration/dose ratios of methadone.	CYP2B6 6/6 is associated with increased concentrations of methadone as compared to CYP2B6 1/1.	28723731	1451226268
CYP2B6	CYP2B61, CYP2B66	1/6	methadone	metabolism/PK	no	The CYP2B6*6 allele was genotyped for using the variants rs3745274 and rs2279343. There was no significant difference in absolute concentrations and concentration/dose ratios of methadone between genotypes.	CYP2B6 1/6 is not associated with concentrations of methadone as compared to CYP2B6 1/1.	28723731	1451226300
CYP2B6	CYP2B61, CYP2B66	1/1	efavirenz	metabolism/PK	not stated	Apparent clearance was 2.2 fold higher for CYP2B6 1/1 compared to CYP2B6 6/6 (p-value is not stated). The reported p-value are for differences in mean AUC between 6/6 + rs3842 CC versus 1/1 +rs3842 TT and between 6/6 + rs3842 CC versus 6/6 + rs3842 CT.	CYP2B6 1/1 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 6/6.	24497997	1183764170
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	not stated	CYP2B6*6 SNPs (rs2279343 and rs3745274) were the only covariates influencing efavirenz clearance and were included in the final model.	CYP2B6 6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	28622951	1448995403
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	yes	A multivariate linear regression model that included CYP2A6 rs28399433, UGT2B7 rs2365062 and CYP2B6 rs28399499 explained 22% variance in efavirenz plasma concentrations. Note: All participants were CYP2B6 slow metabolizers (defined by the following genotypes of two SNPs: rs3745274 TT, or rs3745274 T/rs28399499 C or rs28399499 CC). Alleles have been complemented to the plus chromosomal strand.	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	24729586	1184467538
CYP2B6	CYP2B61, CYP2B66	1/1 + 1/6	efavirenz	metabolism/PK	no	Following a 600-mg oral dose of efavirenz, no significant difference in oral clearance was seen between the two genotype groups. However, the authors suggest this is due to an inadequate number of subjects with the 6/6 genotype (n=3). Those with the 6/6 genotype had a 30% reduction in clearance and a 27% increase in area under the concentration-time curve from 0-infinity (AUC0-inf).	CYP2B6 1/1 + 1/6 is not associated with clearance of efavirenz in healthy individuals as compared to CYP2B6 6/6.	23846872	1184510497
CYP2B6	CYP2B61, CYP2B66	6/6	efavirenz	metabolism/PK	yes	As measured by higher mid-dose EFV plasma concentrations at 12 weeks in patients with the 6/6 genotype (rs3745274 genotype TT and rs2279343 genotype GG). 1/1 was defined as no variant alleles (genotyped for 6 SNPs: rs8192709 64C>T, rs3826711 499C>G, rs3745274 516G>T, rs2279343 785A>G, rs3211369 1375A>G, rs3211371 1459C>T).	CYP2B6 6/6 is associated with decreased metabolism of efavirenz in people with HIV as compared to CYP2B6 1/1.	23399569	1184473220
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	not stated	This study demonstrates PK parameters in patients receiving HAART and rifampin anti-TB co-treatment and suggests reduced dosing for all patients being co-treated for HIV/TB and further reductions for CYP2B6*6.	CYP2B6 6 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 1.	27045425	1447984366
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	yes	Multivariate analysis showed that this SNP contributed significantly to variability of efavirenz plasma concentrations: CYP2A6 1093C>T (rs28399454), CYP2B6 516G>T (rs3745274), CYP2B6 983T>C (rs28399499) contributed 27%, 43%, and 29% of the total variance in efavirenz plasma levels, respectively. The TT genotype was associated with higher efavirenz levels compared to TC over the 6 weeks of treatment (no patients had the CC genotype).	Allele C is associated with metabolism of efavirenz in people with HIV Infections as compared to allele T.	24316028	1184473165
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	yes	As determined by significantly higher efavirenz plasma levels. This SNP was only significant in composite analysis with rs3745274: extensive metabolizers were defined as having no variant alleles at positions 516 (allele G) or (983 allele T), intermediate metabolizers had a single variant at one of the positions but not both, slow metabolizers (described as "poor" here) had 2 variant alleles (either genotype 516TT, 983CC, or 516 GT with 983 TC). Significant after Bonferroni correction for multiple comparisons.	Allele C (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele T (assigned as normal metabolizer phenotype) .	19659438	1184471365
CYP2B6	CYP2B61, CYP2B66	1/6	efavirenz	metabolism/PK	not stated	Apparent clearance was 1.74 fold higher for CYP2B6 1/6 compared to CYP2B6 6/6.	CYP2B6 1/6 is associated with increased metabolism of efavirenz in people with HIV as compared to CYP2B6 6/6.	24497997	1183771932
CYP2B6	CYP2B6*6	*6	efavirenz	metabolism/PK	yes	Steady-state plasma concentration from HIV infected patients treated with EFV were used to calculate baseline biochemistries, CD4 counts, and viral load. The authors used non-linear mixed effect modeling to create a PK model of efavirenz. Significant covariates predicted to affect PK of efavirenz were included in the final model. CYP2B6*6 haplotype was considered a significant factors in covariate analysis and included in the final pharmacokinetic model.	CYP2B6 *6 is associated with metabolism of efavirenz in people with HIV.	24497997	1183944291
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the TT genotype compared to patients with the GT genotype.	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GT.	23399569	1184473241
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Higher median efavirenz plasma concentrations in patients with the TT genotype compared to those with the GG genotype. For patients with the GT genotype, efavirenz concentrations were significantly higher compared to genotype GG, and significantly lower compared to genotype TT (all p<0.001).	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	23172109	1184473309
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	As determined by significantly higher efavirenz plasma levels. Significant after Bonferroni correction for multiple comparisons.	Genotype TT (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG (assigned as normal metabolizer phenotype) .	19659438	1184471312
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the TT genotype compared to patients with the GG genotype.	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	23399569	1184473237
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	Multivariate analysis of factors influencing efavirenz concentrations over 32 weeks of antiretroviral treatment described CYP2B66 (516G>T, rs3745274), CYP2B611 (136A>G, rs35303484) and ABCB1 rs3842A>G genotypes were consistent significant predictors of plasma efavirenz concentration (see supplemental Table 1). The study also showed that long-term efavirenz auto-induction was more pronounced in patients with the CYP2B1/1 genotype compared to those carrying rs3745274 allele T and/or rs35303484 allele G. The study states that the CYP2B66, 11 and ABCB1 rs3842A>G genotypes were associated with higher efavirenz plasma concentrations.	Genotypes GT + TT is associated with concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	25303294	1185234900
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	As shown by increased plasma concentrations (units = mg/L) for those with the TT genotype compared to those with the GG genotype. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	23254426	1183491412
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	yes	As shown by increased plasma concentrations (units = mg/L) for those with the GT genotype compared to those with the GG genotype. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	23254426	1183491421
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Association with significantly increased efavirenz plasma levels. Was significant at week 6, 12 of treatment and 1 month after rifampicin discontinuation.	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	20338069	1184988061
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	in both pregnant and postpartum women. Efavirenz exposure was significantly reduced during pregnancy as compared to postpartum, especially in patients with the GG genotype.	Allele T is associated with decreased clearance of efavirenz in people with HIV Infections as compared to allele G.	25669165	1444698851
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	As shown by increased plasma concentrations (units = mg/L) for those with the TT genotype compared to those with the GT genotype. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	23254426	1183491417
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	yes	Higher EFV plasma levels were observed in patients with the GT genotype vs GG (only statistically significant in patients co-treated with rifampicin-based anti-TB treatment).	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	24316028	1184473123
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	not stated	A systematic review. The authors only state that in the reviewed studies, patients with the slow metabolizer phenotype (associated with the TT genotype) had increased concentrations of efavirenz.	Genotype TT is associated with increased concentrations of efavirenz in people with Hepatitis B and HIV Infections as compared to genotypes GG + GT.	29624706	1449275102
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	As determined by significantly higher efavirenz plasma levels. Composite analysis with rs3745274: extensive metabolizers were defined as having no variant alleles at positions 516 (allele G) or (983 allele T), intermediate metabolizers had a single variant at one of the positions but not both, slow metabolizers (described as "poor" here) had 2 variant alleles (either genotype 516TT, 983CC, or 516 GT with 983 TC). Significant after Bonferroni correction for multiple comparisons.	Allele T (assigned as poor metabolizer phenotype) is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to allele G (assigned as normal metabolizer phenotype) .	19659438	1184471369
CYP2B6	CYP2B61, CYP2B626, CYP2B6*6	1/26 + 6/6 + 6/26	efavirenz	dosage	not stated	Efavirenz dosages were reduced in patients with these genotypes and high concentrations (>6000 ng/mL) with successful HIV suppression.	CYP2B6 1/26 + 6/6 + 6/26 is associated with decreased dose of efavirenz in people with HIV.	17918089	1448261257
CYP2B6	rs2279343	GG	efavirenz	metabolism/PK	no	No differences between genotypes AA, AG and GG and drug plasma concentrations were seen.	Genotype GG is not associated with metabolism of efavirenz or nevirapine in people with HIV Infections as compared to genotype AA.	20625352	1184349357
CYP2B6	rs2279343	GG	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the GG genotype compared to patients with the AA genotype.	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	23399569	1184473249
CYP2B6	rs2279343	GG	efavirenz	metabolism/PK	no	No significant difference in mid-dose EFV plasma concentrations at 12 weeks were seen between patients with the GG genotype and AG genotype.	Genotype GG is not associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AG.	23399569	1184473257
CYP2B6	CYP2B61, CYP2B628	*28	efavirenz	metabolism/PK	not stated	The report of a novel SNP, identified in an individual with high efavirenz plasma exposure who had experienced efavirenz toxicity. The *28 allele results in a premature stop codon and consequently a truncated protein.	CYP2B6 28 is associated with increased exposure to efavirenz in people with HIV as compared to CYP2B6 1.	17235330	1447962916
CYP2B6	rs3745274	T	efavirenz	efficacy	no	The T allele is not associated with an increased risk for virological failure (detectable viral load despite 48 weeks of highly active antiretroviral therapy (HAART) treatment) compared to the G allele.	Allele T is not associated with increased resistance to efavirenz, lamivudine, nevirapine and zidovudine in people with HIV Infections as compared to allele G.	23996099	1183680826
CYP2B6	rs3745274	TT	nevirapine	"toxicity","metabolism/PK"	yes		Genotype TT is associated with decreased clearance of nevirapine in children with HIV Infections as compared to genotypes GG + GT.	21393201	827849230
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	not stated	Authors describe a population pharmacokinetics covariate model for efavirenz which included the effect of the TT genotype on oral clearance.	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections.	24145522	1184233697
CYP2B6	CYP2B61, CYP2B66	*6	cyclophosphamide	metabolism/PK	yes	but there was no effect on progression-free survival.	CYP2B6 6 is associated with decreased clearance of cyclophosphamide in children with Lymphoma, B-Cell as compared to CYP2B6 1/*1.	26773420	1447678899
CYP2B6	rs28399499	CT	efavirenz	metabolism/PK	yes	at month 1, but not significant at month 3 and 24 (p = 0.028 at month 1; p = 0.589 and 0.411 at months 3 and 24).	Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	28816644	1448665545
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	28718515	1448821568
CYP2B6	rs3745274	GT + TT	ritonavir	metabolism/PK	no		Genotypes GT + TT are not associated with concentrations of ritonavir in children with HIV Infections as compared to genotype GG.	28718515	1448821818
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Allele also known as CYP2B6*6.	Genotype TT is associated with increased concentrations of efavirenz in children with HIV Infections.	28886044	1448994415
CYP2B6	rs35303484	GG	efavirenz	metabolism/PK	yes	Allele also known as CYP2B6*11.	Genotype GG is associated with increased concentrations of efavirenz in children with HIV Infections.	28886044	1448994422
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	no	This is stated in the paper, but supporting data is not shown. Allele also known as CYP2B6*18.	Allele C is not associated with concentrations of efavirenz in children with HIV Infections as compared to allele T.	28886044	1448994431
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	no		Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	26831894	1448997108
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	22481606	1448997257
CYP2B6	rs28399499	CT	efavirenz	metabolism/PK	yes		Genotype CT is associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype TT.	22481606	1448997264
CYP2B6	rs3745274	T	efavirenz	efficacy	yes	Children with the T/T genotype (3.0 L/h/m2) had a lower CL/F rate for EFV than did those with the G/T genotype (5.7 L/h/m2; P = 0.02) and the G/G genotype (7.0 L/h/m2; P = 0.003).	Allele T is associated with decreased clearance of efavirenz in children with HIV Infections as compared to allele G.	17356468	1449156665
CYP2B6	rs3745274	GG + GT	methadone	dosage	yes	Patients with the GG or GT genotype required an increased mean daily methadone dose (mg/day) as compared to those with the TT genotype. Please note that this SNP was found to be in strong LD (D' = 1 and r2 = 0.9) with rs2279343 in this sample population.	Genotypes GG + GT are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype TT.	21790905	1183698962
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	When considered as part of a composite (rs3745274 T, rs28399499 C, and rs4803419 T), the T allele was strongly associated with plasma efavirenz concentrations (plasma [EFV]) [beta=0.28, 95% CI (0.21, 0.35) p=2.4 E-11]. In a final multivariable model the T allele was associated with a 31% increased in plasma [EFV] (beta=0.27). Post-hoc sensitivity analysis, in which two extreme outliers were excluded from analysis (N=111), showed that the T allele was associated with a 33% increase in plasma [EFV]. Multi-level mixed effects models predicted plasma [EFV] as a function of 1) fixed age effect, time after dose, CYP2B6 composite genotype T,C,T and 2) random effects of the individual to account for w/in individual correlations, the genotypes TT and GT were associated with a 2.9 fold increase in and a 1.5 fold increase in plasma [EFV], respectively.	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	25611810	1446905193
CYP2B6	rs4803419	T	efavirenz	metabolism/PK	yes	When considered as part of a composite (rs3745274 T, rs28399499 C, and rs4803419 T), the T allele was strongly associated with plasma efavirenz concentrations (plasma [EFV]) [beta=0.28, 95% CI (0.21, 0.35) p=2.4 E-11]. In a final multivariable model the T allele was associated with a 6% increase in plasma [EFV] (beta=0.06). Post-hoc sensitivity analysis, in which two extreme outliers were excluded from analysis (N=111), showed that the T allele was associated with a 12% increase in plasma [EFV]. Multi-level mixed effects models predicted plasma [EFV] as a function of 1) fixed age effect, time after dose, CYP2B6 composite genotype T,C,T and 2) random effects of the individual to account for w/in individual correlations, genotype TT and CT were associated with a 1.4 and 1.2 fold increase in plasma [EFV], respectively.	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele C.	25611810	1446905219
CYP2B6	rs2279345	TT	efavirenz	metabolism/PK	yes	Efavirenz plasma concentrations were highest in patients with the TT genotype >TC >CC. This association remained statistically significant in multi-variate analysis, along with aspartate aminotransferase and blood urea nitrogen.	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	24477223	1183703687
CYP2B6	rs2279345	CC	efavirenz	metabolism/PK	yes	Significantly lower efavirenz plasma levels were observed in patients with the CC genotype compared to TT at 12 weeks of antiretroval treatment (during anti-TB treatment which included rifampin), and at 24 weeks (after rifampin discontinuation). All patients had the CYP2B61/1 haplotype (as determined by 7 SNPs) before being assessed by this SNP. Please note; this SNP was described as 18492T>C (and previous studies by this group provided the rsID).	Genotype CC is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.	24492364	1184467298
CYP2B6	rs2279345	T	efavirenz	metabolism/PK	yes	this was only significant in the Standard dose group (TDF 300 mg, 3TC 300 mg plus EFV 600 mg) not the low dose group (TDF 200 mg, 3TC 300 mg plus EFV 400 mg once daily).	Allele T is associated with decreased concentrations of efavirenz in people with HIV Infections as compared to allele C.	32838647	1451261580
CYP2B6	rs4803419	CT + TT	efavirenz	metabolism/PK	no	The association between this variant and efavirenz concentration is not statistically significant. However, TT carries had lower Tmax and the authors felt that this variants influences CYP2B6 activity score stating that CYP2B6 activity score model based on two CYP2B6 SNPs (G516T and rs4803419) predicted efavirenz disposition better than G516T alone.	Genotypes CT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype CC.	31628422	1451127180
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	yes	When considered as part of a composite (rs3745274 T, rs28399499 C, and rs4803419 T), the C allele was strongly associated with plasma efavirenz concentrations (plasma [EFV]) [beta=0.28, 95% CI (0.21, 0.35) p=2.4 E-11]. In a final multivariable model the C allele was associated with a 46% increased in plasma [EFV] (beta=0.27). Post-hoc sensitivity analysis, in which two extreme outliers were excluded from analysis (N=111), showed that the C allele was associated with a 48% increase in plasma [EFV]. Multi-level mixed effects models predicted plasma [EFV] as a function of 1) fixed age effect, time after dose, CYP2B6 composite genotype T,C,T and 2) random effects of the individual to account for w/in individual correlations, genotype CT was associated with a 2.1 fold increase in plasma [EFV].	Allele C is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele T.	25611810	1446905210
CYP2B6	rs707265	AA	efavirenz	metabolism/PK	no		Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	26779253	1447680801
CYP2B6	CYP2B61, CYP2B618	*18	efavirenz	metabolism/PK	yes		CYP2B6 18 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	26655325	1448994001
CYP2B6	CYP2B61, CYP2B62	*2	efavirenz	metabolism/PK	no		CYP2B6 2 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	26655325	1449157006
CYP2B6	CYP2B6*4	*4	propofol	"other","metabolism/PK"	no		CYP2B6 *4 is not associated with metabolism of propofol.	22006347	827783823
CYP2B6	CYP2B6*6	*6	propofol	"other","metabolism/PK"	no		CYP2B6 *6 is not associated with metabolism of propofol.	22006347	827783818
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	19218571	1448993700
CYP2B6	rs3745274	T		metabolism/PK	no		Allele T is not associated with concentrations of (S)-EDDP as compared to allele G.	28184434	1449171099
CYP2B6	rs3211371	TT	nevirapine	"toxicity","metabolism/PK"	no		Genotype TT is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CC + CT.	19228205	827848942
CYP2B6	rs8100458	CT + TT	efavirenz	metabolism/PK	no		Genotypes CT + TT are not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	22471906	1448993954
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	18784455	1448997679
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz as compared to genotype GG.	19704172	1448997483
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	17918089	1448995941
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	24831655	1448997232
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	"Among individuals homozygous and heterozygous for CYP2B6 516 G>T, the EFV concentration was higher by a median of 4.9 (IQR 3.6; 6.4) µg/mL (P < 0.0001) and 1.1 (IQR 0.3; 2.0) µg/mL (P = 0.01), respectively, compared with the wild type."	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	25974723	1448993691
CYP2B6	rs3745274	TT	efavirenz	efficacy	yes	"CYP2B6 516 G>T polymorphism was found to be significantly associated with virological outcomes in patients receiving EFV-based regimen; patients belonging to GG/GT genotype were more likely to have an unfavourable outcome (P=0.022)."	Genotype TT is associated with increased response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	24521642	1448993465
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	CYP2B6 516T allele was significantly associ- ated with higher efavirenz plasma level. Subjects received ART containing 600mg efavirenz and were prescribed fixed- dose artemether and lumefantrine for uncomplicated malaria by their primary physician.	Allele T is associated with increased concentrations of efavirenz in women HIV Infections and Malaria as compared to genotype GG.	32209837	1451122240
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	not stated		Genotypes GT + TT are associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	18839779	1448998482
CYP2B6	rs4802101	C	cyclophosphamide	metabolism/PK	yes	The plasma concentration of cyclophosphamide (CPA) 20 hours post dose (C20h) was not significantly different between genotypes, but plasma concentrations of the active CPA metabolite of 4-OH-CPA was significantly influenced by CYP2B6 -750T>C and CYP2C19*2 genotype (p<0.001). Patients with CYP2B6 -750TT genotype had significantly higher 4-OH-CPA concentration (C20h median= 20.9 ng/mL) as compared to the TC and CC genotype (C20h median=12.4 and 10.2 ng/ml, respectively).	Allele C is associated with decreased metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	26456622	1446907636
CYP2B6	rs4803419	C	efavirenz	efficacy	no	No significant association with virologic failure is found for the combinations of CYP2B6 polymorphisms (rs3745274, rs28399499, and rs4803419).	Allele C is not associated with response to efavirenz in people with HIV Infections as compared to allele T.	25461247	1296598723
CYP2B6	CYP2B6*7	*7	propofol	"other","metabolism/PK"	no		CYP2B6 *7 is not associated with metabolism of propofol.	22006347	827783832
CYP2B6	rs2279343	GG	methadone	"dosage","metabolism/PK"	yes		Genotype GG is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype AA.	21902500	827816315
CYP2B6	rs4803419	T		metabolism/PK	no		Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	28184434	1449171104
CYP2B6	rs3745274	T	methadone	metabolism/PK	no		Allele T is not associated with concentrations of methadone as compared to allele G.	28184434	1449171069
CYP2B6	rs8192709	CT		metabolism/PK	yes		Genotype CT is associated with increased concentrations of (S)-EDDP as compared to genotype CC.	28184434	1449171059
CYP2B6	rs3745274	TT	bupropion	metabolism/PK	no	Volunteers were given six different formulations of bupropion and PK parameters were assessed. NMo differences in the ratio of the AUC of metabolite: AUC of bupropion between genotypes.	Genotype TT is not associated with metabolism of bupropion in healthy individuals as compared to genotypes GG + GT.	28685396	1448639034
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	22950382	1448994222
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	not stated		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	18057928	1448997691
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	24521642	1448993476
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	not stated		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	25501988	1448997225
CYP2B6	rs3745274	TT	efavirenz	efficacy	no	No significant difference in median CD4 T cell counts of each genotype at different time points was seen in efavirenz group (p = 0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks 12, 24, 36 and 48 of ART, respectively).	Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	20338069	1448993666
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased exposure to efavirenz in people with HIV Infections as compared to genotype GG.	17047492	1448997743
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	no	This is a case study with a human immunodeficiency virus-positive woman who presented with severe psychosis while she was receiving therapy with efavirenz. Her efavirenz concentration was extremely high.	Genotype TT is associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	15668854	1448998441
CYP2B6	rs3745274	GT + TT		metabolism/PK	yes	Significance was lost following multivariate analysis.	Genotypes GT + TT are associated with increased concentrations of (R)-methadone in people with Opioid-Related Disorders as compared to genotype GG.	30907440	1450374111
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	not stated	This is a case report of 43 year old Caucasian woman that presented with efavirenz induced acute liver failure and drastically elevated levels of efavirenz.	Genotype GT is associated with increased concentrations of efavirenz as compared to genotype GG.	23763943	1449156764
CYP2B6	rs3745274	G	methadone	metabolism/PK	no	There was no significant association between this variant and cessation of opioid use.	Allele G is not associated with response to methadone in people with Opioid-Related Disorders as compared to allele T.	30907440	1450374130
CYP2B6	rs3745274	GG	efavirenz	metabolism/PK	yes	Values of oral clearance were 10.2 L/h, 7.33 L/h and 2.38 L/h for GG, GT, and TT patients, respectively.	Genotype GG is associated with increased clearance of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	27299708	1448104256
CYP2B6	rs12721655	G	cyclophosphamide	efficacy	no		Allele G is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	29938344	1449576807
CYP2B6	rs12721655	G	nevirapine	"toxicity","metabolism/PK"	yes		Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A.	22354160	827848004
CYP2B6	rs2279343	G	nevirapine	"toxicity","metabolism/PK"	yes		Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A.	22354160	827848020
CYP2B6	rs35979566	A	nevirapine	"toxicity","metabolism/PK"	yes		Allele A is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele T.	22354160	827848042
CYP2B6	rs28399499	C	efavirenz	metabolism/PK	not stated	This variant in exon 7 defines the CYP2B618 allele and is part of the 16 allele.	Allele C is associated with decreased metabolism of efavirenz in people with HIV Infections.	16495778	769170863
CYP2B6	rs2279343	G	nicotine	metabolism/PK	not stated	Subjects who had at least one G allele had a higher metabolite ratio (trans-3'-hydroxycotinine to cotinine ratio). The ratio was on average 25% higher (95% CI, 6% to 48%) in subjects carrying a G allele compared with AA genotype allele.	Allele G is associated with increased metabolism of nicotine in people with Tobacco Use Disorder as compared to allele A.	17015050	769169833
CYP2B6	rs8192709	TT	bupropion	metabolism/PK	no	Volunteers were given six different formulations of bupropion and PK parameters were assessed. NMo differences in the ratio of the AUC of metabolite: AUC of bupropion between genotypes.	Genotype TT is not associated with metabolism of bupropion in healthy individuals as compared to genotypes CC + CT.	28685396	1448639028
CYP2B6	rs8109525	AG + GG	varenicline	efficacy	yes	Patients with AG or GG genotypes had a higher success rate of smoking cessation with varenicline (51.2%) compared with carriers of the AA genotypes (33.3%, P=0.03, n=167). The AG or GG genotypes were also associated with a higher odds ratio of success, even in a multivariate analysis adjusting for potential confounders (OR=2.01; 95%CI=1.01 to 4.00; P=0.047).	Genotypes AG + GG is associated with increased response to varenicline in people with Tobacco Use Disorder as compared to genotype AA.	31402421	1450928322
CYP2B6	CYP2B61, CYP2B66	*6	methadone	metabolism/PK	yes	This study found an association with (S)-methadone clearance, specifically.	CYP2B6 6 is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to CYP2B6 1.	27286724	1448104418
CYP2B6	rs45482602	AA	methadone	"dosage","metabolism/PK"	yes		Genotype AA is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	21902500	827816329
CYP2B6	rs3745274	TT	nevirapine	"toxicity","metabolism/PK"	yes		Genotype TT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	19228205	827848963
CYP2B6	rs3745274	T	nevirapine	"toxicity","metabolism/PK"	yes		Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	22354160	827848013
CYP2B6	rs28399499	CC + CT	nevirapine	"toxicity","metabolism/PK"	yes		Genotypes CC + CT are not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype TT.	22354160	827848035
CYP2B6	CYP2B61, CYP2B65	*5	clopidogrel	efficacy	no	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	CYP2B6 5 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2B6 1.	26526111	1448115887
CYP2B6	rs1042389	TT	efavirenz	metabolism/PK	no		Genotype TT is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CC + CT.	26779253	1447680819
CYP2B6	rs3211371	TT	methadone	"dosage","metabolism/PK"	yes		Genotype TT is not associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype CC.	21902500	827816322
CYP2B6	rs3745274	TT	methadone	"dosage","metabolism/PK"	yes		Genotype TT is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype GG.	21902500	827816234
CYP2B6	CYP2B61, CYP2B66	6/6	efavirenz	metabolism/PK	yes		CYP2B6 6/6 is associated with increased concentrations of efavirenz in healthy individuals as compared to CYP2B6 1/1 + 1/6.	27333947	1448995845
CYP2B6	CYP2B61, CYP2B65	1/5	efavirenz	metabolism/PK	no		CYP2B6 1/5 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	17235330	1448996011
CYP2B6	rs7246465	CT + TT	efavirenz	metabolism/PK	yes	"An increase in CYP2B6 activity was also seen among volunteers carrying the rs7246465 variant allele (C/C vs. C/T [38.0% increase; p<0.01] and T/T [67.9% increase; p<0.0001])".	Genotypes CT + TT are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype CC.	28960269	1448997604
CYP2B6	rs8192709	CT + TT	efavirenz	metabolism/PK	no		Genotypes CT + TT are not associated with concentrations of efavirenz in people with HIV Infections as compared to genotype CC.	22471906	1448993933
CYP2B6	rs3745274	GT	nevirapine	"toxicity","metabolism/PK"	yes		Genotype GT is associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotype GG.	19228205	827848956
CYP2B6	CYP2B61, CYP2B638, CYP2B6*6	6 + 38	efavirenz	metabolism/PK	no	This is a case report of an HIV-positive Asian man with extremely high efavirenz plasma levels who developed severe neuropsychiatric symptoms while receiving standard treatment with efavirenz/tenofovir/emtricitabine fixed-dose regimen.	CYP2B6 6 + 38 are associated with decreased clearance of efavirenz as compared to CYP2B6 1/1.	23640958	1449156732
CYP2B6	CYP2B61, CYP2B66	*6	cyclophosphamide	metabolism/PK	yes		CYP2B6 6 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 1/*1.	28181240	1449157325
CYP2B6	rs3745274	T	nevirapine	"other","metabolism/PK"	not stated	The impact of rs3745274 on nevirapine clearance was found to be best described by an additive genetic model that indicated a gene-dose effect: heterozygous patients (GT) showed a 15.3% reduced clearance whereas patients with homozygous TT alleles showed a 30.6% reduced clearance compared with patients with GG alleles. No p-value published.	Allele T is associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele G.	21860339	827784211
CYP2B6	CYP2B6*9	*9	propofol	"other","metabolism/PK"	no		CYP2B6 *9 is not associated with metabolism of propofol.	22006347	827783826
CYP2B6	CYP2B6*5	*5	propofol	"other","metabolism/PK"	no		CYP2B6 *5 is not associated with metabolism of propofol.	22006347	827783829
CYP2B6	CYP2B61, CYP2B66	*6	nicotine	metabolism/PK	not stated	In vitro study which looked at metabolism of nicotine to nicotine iminium and nornicotine.	CYP2B6 6 is associated with decreased metabolism of nicotine as compared to CYP2B6 1.	30906561	1450375324
CYP2B6	CYP2B6*6	6/6	mirtazapine	metabolism/PK	yes	As compared to genotypes 5/5, 4/6, 1/7, 5/6, 1/6, 1/5, 1/4, 1/1. Patients with the CYP2B6 6/6 genotype had significantly higher steady-state plasma concentrations of the S-enantiomer of the metabolite 8-hydroxymirtazapine (S-OH-MIR) compared to those with the other genotypes.	CYP2B6 6/6 is associated with increased metabolism of mirtazapine in people with Depression.	22926595	981502148
CYP2B6	CYP2B6*6	6/6	mirtazapine	efficacy	yes	As compared to genotypes 5/5, 4/6, 1/7, 5/6, 1/6, 1/5, 1/4, 1/1. Response was measured using the Hamilton Depression Rating Scale (HAMD). Patients with the CYP2B6 6/6 genotype had a greater reduction in HAMD scores over 8 weeks of treatment with mirtazapine compared to those with the other genotypes.	CYP2B6 6/6 is associated with increased response to mirtazapine in people with Depression.	22926595	981502166
CYP2B6	CYP2B61, CYP2B618, CYP2B622, CYP2B64, CYP2B65, CYP2B66	1/6 + 1/18	bupropion	metabolism/PK	yes	Light smokers. Individuals with one copy of a reduced function allele (6, 18) were grouped into the "intermediate metabolizer" group. The genotypes within this group were 1/6 (n=53), 1/18 (n=8), 1/6 + 1/5 (compound heterozygote; n=1), 1/6 + 1/22 (compound heterozygote; n=2). Individuals with 1/1 (n=48), 1/4 (n=1), 1/5 (n=4), 1/22 (n=4), and 22/22 (n=1) genotype were considered normal metabolizers. Intermediate metabolizers had decreased hydroxybupropion/bupropion ratios as compared to normal metabolizers. No significant result was seen when considering bupropion levels (p=0.056) or hydroxybupropion levels (p=0.052).	CYP2B6 1/6 + 1/18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 1/1 + 1/4 + 1/5 + 1/22 + 22/22.	23149928	1445403153
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	yes	1/6 and 6/6 had significantly lower efavirenz-8-hydroxylation and significantly decreased CYP2B6 protein compared with 1/1. [Stat_test: Mann-Whitney]	CYP2B6 6 is associated with decreased metabolism of efavirenz in human liver microsomes as compared to CYP2B6 1.	17559344	981419341
CYP2B6	CYP2B6*1	1/1	efavirenz	metabolism/PK	yes	1/1 is associated with low plasma efavirenz concentrations (units = mg/L), as shown through multivariate analysis. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	CYP2B6 1/1 is associated with increased clearance of efavirenz in people with HIV.	23254426	1183491475
CYP2B6	CYP2B6*4	*4	bupropion	"other","metabolism/PK"	yes	CYP2B6 genotypes 1/4, 2/4, 4/5, 4/6 (n=2) had increased clearance as compared to subjects without any CYP2B6 4 allele (1/1, 1/2, 1/5, 1/6, 2/5, 2/6, 5/6, 6/6; n=109) (p=0.001). Bupropion clearance via the 4 allele was 1.66-fold higher compared to the 1 allele after a single dose of 150 mg bupropion. Additionally, those with the 1/4 genotype had increased Cmax and are under the curve (AUC) of hydroxybupropion, as well as ratio of AUC of hydroxybupropion/bupropion as compared to those with the 1/1, 1/5, 1/6, 2/6 and 6/*6, after correction for multiple testing using Bonferroni.	CYP2B6 *4 is associated with increased clearance of bupropion in healthy individuals.	14515060	1043880685
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	Subjects carrying at least one T allele had a significantly increased AUC/DW and significantly decreased CL/F compared to subjects with the GG genotype.	Genotypes GT + TT are associated with increased exposure to efavirenz in healthy individuals as compared to genotype GG.	31628422	1451127146
CYP2B6	rs3211371	CT + TT	efavirenz	metabolism/PK	yes	Subjects carrying at least one T allele had a significantly decreased AUC/DW and significantly increased CL/F compared to subjects with the CC genotype.	Genotypes CT + TT are associated with decreased exposure to efavirenz in healthy individuals as compared to genotype CC.	31628422	1451127150
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	not stated	Analysis was done as CYP2B6 slow metabolizer genotypes grouping (15582CC-516TT-983TT; 9: 15582CC-516GT- 983CT; or 10: 15582CC-516GG-983CC), which were associated with higher plasma efavirenz log10 AUC0–8 hours, log10 maximum concentration (Cmax), and log10 minimum concentration (Cmin) values at days 0 and 21.	Genotype TT is associated with decreased metabolism of efavirenz in women with HIV Infections as compared to genotype GG.	32106141	1451131980
CYP2B6	CYP2B6*6	6/6	efavirenz	metabolism/PK	yes	6/6 is associated with high plasma efavirenz concentrations (units = mg/L), as shown through multivariate analysis. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	CYP2B6 6/6 is associated with decreased clearance of efavirenz in people with HIV.	23254426	1183616504
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	20841522	1448997449
CYP2B6	rs8192709	CC	efavirenz	metabolism/PK	no	No significant difference in plasma concentrations of efavirenz (units = mg/L) were seen between the three genotypes. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment. p-value from univariate analysis with plasma concentration as the dependent variable.	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	23254426	1183491430
CYP2B6	rs3211371	CC	efavirenz	metabolism/PK	no	No significant difference in plasma concentrations of efavirenz (units = mg/L) were seen between the two genotypes. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment. p-value from univariate analysis with plasma concentration as the dependent variable.	Genotype CC is not associated with clearance of efavirenz in people with HIV Infections as compared to genotype CT.	23254426	1183491471
CYP2B6	CYP2B61, CYP2B66	6/6	efavirenz	metabolism/PK	yes		CYP2B6 6/6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	20881953	1448995859
CYP2B6	rs2279343	AA + AG	methadone	dosage	yes	Patients with the AA or AG genotype required an increased mean daily methadone dose (mg/day) as compared to those with the GG genotype. Please note that this SNP was found to be in strong LD (D' = 1 and r2 = 0.9) with rs3745274 in this sample population.	Genotypes AA + AG are associated with increased dose of methadone in people with Heroin Dependence as compared to genotype GG.	21790905	1183698967
CYP2B6	rs3745274	GT + TT	lopinavir	metabolism/PK	no		Genotypes GT + TT are not associated with concentrations of lopinavir in children with HIV Infections as compared to genotype GG.	28718515	1448821800
CYP2B6	CYP2B61, CYP2B66	6/6	sibutramine	metabolism/PK	no	No significant differences in R-sibutramine or S-sibutramine peak plasma concentrations (Cmax) or area under the plasma concentration-time curve from 0 to infinity (AUC) were seen between genotypes. Additionally, no significant differences were seen in these parameters when considering the S-M1, R-M1 and R-M2 metabolites of sibutramine. Lastly, no significant differences were seen in these parameters when patients were given clopidogrel or clarithromycin in addition to sibutramine.	CYP2B6 6/6 is not associated with metabolism of sibutramine in healthy individuals as compared to CYP2B6 1/1.	23381968	1183682115
CYP2B6	CYP2B61, CYP2B622	1/22	bupropion	metabolism/PK	yes	CYP2B6 mRNA expression and bupropion hydroxylase activity were approximately 2-fold higher in livers genotyped -82TC (1/22) as in those genotyped -82TT (1/1).	CYP2B6 1/22 is associated with increased metabolism of bupropion as compared to CYP2B6 1/1.	15722458	1447963480
CYP2B6	rs2279345	CC + CT	efavirenz	metabolism/PK	yes	Patients with the CC and CT genotypes had lower median fasting plasma efavirenz concentrations compared to those with the TT genotype. Patients also were receiving tenofovir and lamivudine. Plasma concentrations were determined 12 weeks after initiation of therapy.	Genotypes CC + CT are associated with increased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	24293076	1183699582
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	cyclophosphamide	efficacy	yes	Patients treated with a combination of fludarabine and cyclophosphamide who have the 1/6 or 6/6 genotype were significantly less likely to achieve a complete response, as compared to those with the 1/1 genotype. Significant results were also found when complete response was combined with nodular partial response, and in multivariate analysis (controlling for age, gender, stage, IGHV mutational status, 11q deletion, and TP53 deletion and/or mutation).	CYP2B6 1/6 + 6/6 are associated with decreased response to cyclophosphamide and fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 1/1.	24128861	1184167044
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	chlorambucil	efficacy	no	No significant effect of CYP2B6*6 on response to chlorambucil was seen. Response was defined in three ways: complete response (CR; p = 1.0, OR = 1.06 (0.3 - 4.37)); CR or nodular partial response (nPR; p = 1.0, OR = 1.04 (0.5 - 2); CR, nPR or partial response (p = 0.493, OR = 0.75 (0.37 - 1.55)). None of these definitions was associated with the allele.	CYP2B6 1/6 + 6/6 is not associated with response to chlorambucil in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 1/1.	24128861	1184167080
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	fludarabine	efficacy	yes	No significant effect of CYP2B6*6 on response to fludarabine was seen. Response was defined in three ways: complete response (CR; p = 0.580, OR = 0.60 (0.14 - 2.28)); CR or nodular partial response (nPR; p = 0.175, OR = 0.53 (0.21 - 1.28); CR, nPR or partial response (p = 0.173, OR = 0.42 (0.12 - 1.36)). None of these definitions was associated with the allele.	CYP2B6 1/6 + 6/6 is not associated with response to fludarabine in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to CYP2B6 1/1.	24128861	1184167098
CYP2B6	CYP2B61, CYP2B66	6/6	efavirenz	metabolism/PK	yes	The total clearance of efavirenz was ~30% lower in those with the 6/6 genotype as compared to those with the 1/1 or 1/6 genotype. Population pharmacokinetic modeling.	CYP2B6 6/6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 1/1 + 1/6.	24142869	1184165591
CYP2B6	rs8192719	T	methadone	metabolism/PK	no		Allele T is not associated with concentrations of methadone as compared to allele C.	28184434	1449171084
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	25831219	1448997218
CYP2B6	rs8192709	CC	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the CC genotype compared to patients with the CT genotype.	Genotype CC is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	23399569	1184473233
CYP2B6	rs3211371	CC	efavirenz	metabolism/PK	yes	No significant difference in mid-dose EFV plasma concentrations at 12 weeks were seen between genotypes.	Genotype CC is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CT.	23399569	1184473261
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Higher EFV plasma levels were observed in patients with the TT genotype.	Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	24316028	1184473116
CYP2B6	rs3745274	GT + TT	nevirapine	metabolism/PK	no	No difference in nevirapine plasma concentration was seen.	Genotypes GT + TT is not associated with metabolism of nevirapine in people with HIV Infections as compared to genotype GG.	20625352	1184349353
CYP2B6	rs36118214	GG	efavirenz	metabolism/PK	yes	As determined by significantly different efavirenz plasma levels in patients with genotypes in the order AA<AG<GG. Significant after Bonferroni correction for multiple comparisons. This SNP was not in linkage disequilibrium with rs3745274 (516G>T) (r squared = 0.242).	Genotype GG is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype AA.	19659438	1184471413
CYP2B6	CYP2B61, CYP2B613, CYP2B66, CYP2B69	1/6 + 1/9 + 1/6 + 1/9 + 1/13 + 6/9 + 9/9	prasugrel	efficacy	no	Plasma concentrations of active drug metabolite and platelet inhibition in response to prasugrel were assessed in the healhy subject cohort, and clinical outcome(risk of cardiovascular death, myocardial infarction or stroke) was assessed in the large cohort of patients with acute coronary syndromes.	CYP2B6 1/6 + 1/9 + 1/6 + 1/9 + 1/13 + 6/9 + 9/9 (assigned as poor metabolizers and intermediate metabolizers phenotype) is not associated with response to prasugrel in healthy individuals as compared to CYP2B6 1/1 (assigned as normal metabolizer phenotype) .	19414633	1184471526
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	not stated	A PK model to predict efavirenz clearance values for the different genotypes included age and weight.	Genotype TT is associated with decreased clearance of efavirenz in children with HIV Infections as compared to genotype GG.	22057858	1184512470
CYP2B6	CYP2B61, CYP2B618	1/18	efavirenz	metabolism/PK	yes	Note: combined analysis of loss of function alleles - diplotypes described in the population were n=2 6/6, n=3 1/18 n=2 1/9. Mean log efavirenz trough concentrations increased with the number of loss of function alleles.	CYP2B6 1/18 is associated with decreased metabolism of efavirenz in people with HIV.	20952418	1184988346
CYP2B6	rs3745274	T	cyclophosphamide	efficacy	no		Allele T is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A.	29938344	1449576829
CYP2B6	rs70950385	CA/CA	efavirenz	metabolism/PK	yes	The rs70950385 and rs1042389 variant alleles were associated with a decrease in CYP2B6 activity when comparing Plasma efavirenz AUC0-48 ratios (8-OH-EFV/EFV)) between AG/AG and CA/CA genotypes (32.7%; p<0.05).	Genotype CA/CA is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype AG/AG.	28960269	1448997587
CYP2B6	rs28399499	C	efavirenz	efficacy	no	No significant association with virologic failure is found for the combinations of CYP2B6 polymorphisms (rs3745274, rs28399499, and rs4803419).	Allele C is not associated with response to efavirenz in people with HIV Infections as compared to allele T.	25461247	1296598716
CYP2B6	rs3745274	G	methadone	dosage	no	Methadone maintenance dose was not associated with genotype of the SNP but it was correlated to the highest dose ever used. Multiple doses versus single dose, body weight, history of cocaine dependence and ethnicity (Asian>Caucasian>African) were independently associated with methadone dose in multiple regression analysis.	Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele T.	25556837	1444695465
CYP2B6	rs3745274	GT + TT	propofol	dosage	yes	The total propofol doses based on the GG or GT/TT genotypes were 151.5 ± 64.2 mg and 129.3 ± 44.6 mg, respectively (p = 0.043). This variant decreases the metabolism of the drug, accounts for approximately 7 % of the drug dosage in patients under general anaesthesia.	Genotypes GT + TT are associated with decreased dose of propofol as compared to genotype GG.	26141406	1444933003
CYP2B6	CYP2B61, CYP2B66	*6	ketamine	metabolism/PK	yes	Median plasma clearance in the 6/6 genotype was 21.6 L/h, 1/6 genotype 40.6 L/h and 1/1 genotype 68.1 L/h. In linear regression analysis the 6 allele explained 40%, 43%, and 41% of the variability in ketamine clearance when the dose was 100, 300 and 500 mg/24 hrs. The authors state that the study was insufficiently powered to study the association between adverse effects and genotype and most of the adverse events were reported in patients with the CYP2B6 1/*1 genotype.	CYP2B6 6 is associated with decreased clearance of ketamine in people with Neoplasms and Pain as compared to CYP2B6 1.	25702819	1444698157
CYP2B6	rs2279343	AA	cyclophosphamide	"efficacy","toxicity","metabolism/PK"	no		Genotype AA is not associated with increased response to cyclophosphamide in people with Lupus Nephritis as compared to genotypes AG + GG.	26222310	1447676115
CYP2B6	rs3745274	T	methadone	metabolism/PK	yes		Allele T is associated with decreased clearance of methadone in people with Opioid-Related Disorders as compared to allele G.	25456329	1447520749
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	methadone	metabolism/PK	yes	PK measures were AUC, clearance, peak concentration, exposure.	CYP2B6 1/6 + 6/6 is associated with decreased clearance of methadone in healthy individuals as compared to CYP2B6 1/1.	26389554	1447944325
CYP2B6	CYP2B61, CYP2B64, CYP2B6*6	1/4 + 4/6	methadone	metabolism/PK	yes	PK measures were AUC, clearance, peak concentration, exposure.	CYP2B6 1/4 + 4/6 is associated with increased clearance of methadone in healthy individuals as compared to CYP2B6 1/1.	26389554	1447944355
CYP2B6	CYP2B61, CYP2B618, CYP2B622, CYP2B64, CYP2B65, CYP2B66	6/6 + 6/18	bupropion	metabolism/PK	yes	Light smokers. Individuals with two copies of a reduced function allele (6, 18) were grouped into the "slow metabolizer" group. The genotypes within this group were 6/6 (n=22), 6/18 (n=8), 6/6 + 1/22 (compound heterozygote; n=1). Individuals with 1/1 (n=48), 1/4 (n=1), 1/5 (n=4), 1/22 (n=4), and 22/22 (n=1) genotype were considered normal metabolizers. Slow metabolizers had decreased hydroxybupropion levels and hydroxybupropion/bupropion ratios as compared to normal metabolizers. No significant result was seen when considering bupropion levels (p=0.297).	CYP2B6 6/6 + 6/18 is associated with decreased metabolism of bupropion in people with Tobacco Use Disorder as compared to CYP2B6 1/1 + 1/4 + 1/5 + 1/22 + 22/22.	23149928	1445403174
CYP2B6	CYP2B6*6	*6	bupropion	efficacy	no	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide. There was no difference in success rate between genotype groups when looking over all patients, patients in the bupropion group, varenicline group, or the bupropion and varenicline group.	CYP2B6 *6 is not associated with response to bupropion in people with Tobacco Use Disorder.	26153084	1446765775
CYP2B6	rs3211371	T	bupropion	efficacy	no	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide. There was no difference in success rate between genotype groups when looking over all patients, patients in the bupropion group, varenicline group, or the bupropion and varenicline group.	Allele T is not associated with response to bupropion in people with Tobacco Use Disorder as compared to allele C.	26153084	1446765760
CYP2B6	rs3745274	T	bupropion	efficacy	no	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide. There was no difference in success rate between genotype groups when looking over all patients, patients in the bupropion group, varenicline group, or the bupropion and varenicline group.	Allele T is not associated with response to bupropion in people with Tobacco Use Disorder.	26153084	1446765769
CYP2B6	rs7254579	C	cyclophosphamide	metabolism/PK	yes	This SNP had a small but significant effect on cyclophosphamide (CPA) metabolite plasma concentrations (4-OH-CPA), but not on CPA concentrations (Bonferroni corrected p-value= 0.0056).	Allele C is associated with metabolism of cyclophosphamide in people with Lupus erythematosus as compared to allele T.	26456622	1446907707
CYP2B6	rs4803419	T	cyclophosphamide	metabolism/PK	no	This SNP had a small effect on cyclophosphamide (CPA) metabolite plasma concentrations (4-OH-CPA), but did not reach significance (Bonferroni corrected p-value= 0.0056).	Allele T is not associated with metabolism of cyclophosphamide in people with as compared to allele C.	26456622	1446907684
CYP2B6	rs2279343	G	cyclophosphamide	metabolism/PK	no		Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele A.	26456622	1446907896
CYP2B6	rs3745274	G	cyclophosphamide	metabolism/PK	no		Allele G is not associated with metabolism of cyclophosphamide in people with as compared to allele T.	26456622	1446907885
CYP2B6	rs4803419	CC	efavirenz	metabolism/PK	no		Genotype CC is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	26779253	1447680740
CYP2B6	CYP2B61, CYP2B66	*6	bupropion	metabolism/PK	yes	Individuals with the CYP2B61/1 genotype showed a significantly higher mean AUC hydroxybupropion/AUC bupropion than individuals car-rying the CYP2B61/6 and CYP2B66/6 variants (17.1±6.23 vs. 10.3±4.53, P=0.003, and 17.1±6.23 vs. 9.41±2.84, P=0.002, respectively). No significant difference was found between the CYP2B61/6 and CYP2B66/6 genotype groups (10.3 ± 4.53 vs. 9.41 ± 2.84, P = 0.715).	CYP2B6 6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 1/*1.	26580670	1447521014
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes		Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	26779253	1447680746
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	ON EFV-containing therapy for >7 days, absence of interacting drugs, no co-infection, drug intake 12 hrs (+/- 3 hrs) before blood draw, reported medication adherence above 90%. Receive 600 mg EFV once daily.	Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	26774523	1447680376
CYP2B6	CYP2B6*6	*6	bupropion	metabolism/PK	yes	In human liver microsomes. The CYP2B6*6B haplotype was more commonly observed in livers with low bupropion hydroxylation activity as compared to those with high hydroxylation activity. This was also significant when considering only Caucasian individuals.	CYP2B6 *6 is associated with decreased metabolism of bupropion.	15083067	1445556633
CYP2B6	CYP2B61, CYP2B66, CYP2B6*9	6/9 + 1/6 + 6/6	sertraline	metabolism/PK	yes	2B61/6 n=13 2B66/6 n=7 2B66/9 n=3 1/1=27	CYP2B6 6/9 + 1/6 + 6/6 is associated with increased concentrations of sertraline in people with Depressive Disorder, Major as compared to CYP2B6 1/1.	26830411	1447950063
CYP2B6	CYP2B6 poor metabolizer genotype		efavirenz	metabolism/PK	not stated	Genotype for metabolizer status determined from rs3745274, rs28399499, and rs4803419. Patients were taking both efavirenz and antituberculosis therapy rifampin.	CYP2B6 poor metabolizer genotype is associated with increased clearance of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 normal metabolizer genotype.	25722197	1447947568
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	Significant association was seen at T=12 and 18 hours.	Allele T is associated with increased concentrations of efavirenz in people with HIV Infections as compared to allele G.	27655857	1448265859
CYP2B6	CYP2B61, CYP2B69	*9	clopidogrel	efficacy	no	All patients were on double-antiplatelet therapy (aspirin, 125 mg/day; clopidogrel, 75 mg/day) at least 7 days before carotid artery stenting.	CYP2B6 9 is not associated with response to clopidogrel in people with Carotid Artery Diseases as compared to CYP2B6 1.	26526111	1448115897
CYP2B6	rs3745274	T	nevirapine	metabolism/PK	yes	CYP2B6 516 G>T (rs3745274) was associated independently with higher nevirapine plasma concentrations in pregnant and postpartum women in a multivariate linear regression analysis.	Allele T is associated with increased concentrations of nevirapine in women as compared to allele G.	27195527	1448108757
CYP2B6	rs28399499	C	nevirapine	metabolism/PK	yes	CYP2B6 983 T > C (rs28399499) was associated independently with higher nevirapine plasma concentrations in pregnant and postpartum women in a multivariate linear regression analysis.	Allele C is associated with increased concentrations of nevirapine in women as compared to allele T.	27195527	1448108791
CYP2B6	CYP2B61, CYP2B66	*6	bupropion	metabolism/PK	no	The AUC of steady state was compared.	CYP2B6 6 is associated with increased steady-state concentration of bupropion in women with Pregnancy as compared to CYP2B6 1.	27528039	1448257516
CYP2B6	CYP2B61, CYP2B66	*6	bupropion	metabolism/PK	no		CYP2B6 6 is associated with decreased metabolism of bupropion in women with Pregnancy as compared to CYP2B6 1.	27528039	1448257502
CYP2B6	rs28399499	CC	nevirapine	"toxicity","metabolism/PK"	no		Genotype CC is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to genotypes CT + TT.	19228205	827848949
CYP2B6	rs28399499	CC	efavirenz	metabolism/PK	yes		Genotype CC is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes CT + TT.	26779253	1447680778
CYP2B6	rs35303484	G	efavirenz	metabolism/PK	yes	Multivariate analysis of factors influencing efavirenz concentrations over 32 weeks of antiretroviral treatment described CYP2B66 (516G>T, rs3745274), CYP2B611 (136A>G, rs35303484) and ABCB1 rs3842A>G genotypes were consistent significant predictors of plasma efavirenz concentration (see supplemental Table 1). The study also showed that long-term efavirenz auto-induction was more pronounced in patients with the CYP2B1/1 genotype compared to those carrying rs3745274 allele T and/or rs35303484 allele G. The study states that the CYP2B66, 11 and ABCB1 rs3842A>G genotypes were associated with higher efavirenz plasma concentrations.	Allele G is associated with concentrations of efavirenz in people with HIV Infections as compared to allele A.	25303294	1185234929
CYP2B6	rs35303484	AA	efavirenz	metabolism/PK	no		Genotype AA is not associated with concentrations of efavirenz in people with HIV Infections as compared to genotypes AG + GG.	26779253	1447680733
CYP2B6	rs3745274	TT	nevirapine	metabolism/PK	yes	Nevirapine was given as part of HAART therapy.	Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	26348712	1448110402
CYP2B6	rs2279343	AA + AG	propofol	metabolism/PK	yes	Population pharmacokinetic modeling. Patients with the AA or AG genotype had a significantly decreased elimination rate from the central compartment (Ke) as compared to those with the GG genotype. Patients with the AA or AG genotype also had a decreased clearance of propofol as compared to those with the GG genotype, though no statistical information was provided. Propofol anesthesia.	Genotypes AA + AG is associated with decreased clearance of propofol as compared to genotype GG.	28154789	1448592786
CYP2B6	rs3745274	T	lumefantrine	metabolism/PK	no	Median concentrations of lumefantrine 7 days after beginning treatment with artemether-lumefantrine were not significantly different and no more likely to have median concentrations of lumefantrine >600 ng/ml between genotypes.	Allele T is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele G.	28673292	1449003506
CYP2B6	rs28399499	C	lumefantrine	metabolism/PK	no	Median concentrations of lumefantrine 7 days after beginning treatment with artemether-lumefantrine were not significantly different and no more likely to have median concentrations of lumefantrine >600 ng/ml between genotypes.	Allele C is not associated with concentrations of lumefantrine in women with Malaria and Pregnancy as compared to allele T.	28673292	1449003516
CYP2B6	rs28399499	C	efavirenz	efficacy	no		Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.	22951632	1448993530
CYP2B6	rs34097093	C	efavirenz	efficacy	no		Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.	22951632	1448993538
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	not stated		CYP2B6 6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	23734829	1448997246
CYP2B6	rs2279343	G	efavirenz	metabolism/PK	no	at month 1, 3 and 24 (p= 0.546 at month 1; p=0.453 abd 0.589 at months 3 and 24).	Allele G is not associated with increased concentrations of efavirenz in children with HIV Infections as compared to allele A.	28816644	1448665077
CYP2B6	rs1042389	TT	efavirenz	metabolism/PK	yes	The rs70950385 and rs1042389 variants were in complete linkage disequilibrium (r2=1, D’=1).	Genotype TT is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype CC.	28960269	1448997614
CYP2B6	rs2279343	GG	efavirenz	metabolism/PK	yes		Genotype GG is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes AA + AG.	20841522	1448997456
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	at month 1, 3 and 24 (p < 0.004 at month 1; p < 0.001 at both months 3 and 24).	Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	28816644	1448663995
CYP2B6	rs2279343	AG + GG	efavirenz	metabolism/PK	yes		Genotypes AG + GG are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype AA.	22481606	1448997270
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	20720517	1448997462
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	19124658	1448997672
CYP2B6	rs28399499	CC + CT	efavirenz	metabolism/PK	not stated	This is for CYP2B6 983T>C.	Genotypes CC + CT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype TT.	28692529	1448636182
CYP2B6	CYP2B61, CYP2B616	*16	efavirenz	metabolism/PK	yes		CYP2B6 16 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	16495778	1448997750
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	not stated	This is for CYP2B6 516G>T.	Genotypes GT + TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	28692529	1448636173
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	no	This is a case study of the emergence of psychosis in a 12-year old white girl with an increased efavirenz concentration and heterozygous gene polymorphism of the CYP2B6-G516T.	Genotype GT is associated with increased concentrations of efavirenz in women HIV Infections as compared to genotype GG.	17968817	1448997712
CYP2B6	rs8192709	CT	efavirenz	efficacy	no		Genotype CT is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype CC.	22951632	1448993550
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	This variant is also associated with lower efavirenz clearance. "CYP2B6 position 516 TT homozygotes have a higher probability of experiencing more-prolonged plasma efavirenz exposure following discontinuation of antiretroviral therapy than do GG homozygotes or GT heterozygotes.".	Genotype TT is associated with increased exposure to efavirenz in people with HIV Infections as compared to genotypes GG + GT.	16392089	1448997797
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	yes	Subjects homozygous for CYP2B6*6 (G516T, A785G) displayed 21% lower apparent oral clearance.	CYP2B6 6 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 1/*1.	19916993	1448995871
CYP2B6	CYP2B61, CYP2B611	*11	efavirenz	metabolism/PK	yes	Subjects homozygous for CYP2B6*11 displayed 20% lower apparent oral clearance as compared to wild type.	CYP2B6 11 is associated with decreased clearance of efavirenz in healthy individuals as compared to CYP2B6 1/*1.	19916993	1448995884
CYP2B6	rs2279343	AG + GG	efavirenz	metabolism/PK	yes		Genotypes AG + GG are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype AA.	26107645	1448997136
CYP2B6	rs3745274	TT	nevirapine	metabolism/PK	yes		Genotype TT is associated with decreased metabolism of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	28947469	1449001754
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	yes		CYP2B6 6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	16495778	1448997763
CYP2B6	rs3745274	TT	3,4-methylenedioxymethamphetamine	metabolism/PK	yes	Measures of PK compared were MDMA Cmax (P<0.05 for higher concentration in subjects with TT genotype compared to GG genotype) and MDMA/MDA AUC ratio (P<0.05 for higher ratios in TT vs GT+GG group.	Genotype TT is associated with increased concentrations of 3,4-methylenedioxymethamphetamine in healthy individuals as compared to genotype GG.	28117133	1448573444
CYP2B6	rs3745274	T	lumefantrine	efficacy	no		Allele T is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele G.	28673292	1449003645
CYP2B6	rs28399499	C	lumefantrine	efficacy	no		Allele C is not associated with response to lumefantrine in women with Malaria and Pregnancy as compared to allele T.	28673292	1449003652
CYP2B6	CYP2B61, CYP2B66	*6	efavirenz	metabolism/PK	yes		CYP2B6 6 is associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	26655325	1448993987
CYP2B6	rs2279343	AA	bupropion	metabolism/PK	no	Volunteers were given six different formulations of bupropion and PK parameters were assessed. NMo differences in the ratio of the AUC of metabolite: AUC of bupropion between genotypes.	Genotype AA is not associated with metabolism of bupropion in healthy individuals as compared to genotypes AG + GG.	28685396	1448639039
CYP2B6	rs4803419	CT	levonorgestrel	metabolism/PK	yes	in patients treated with levonorgestrel implant plus efavirenz. The authors hypothesize that the high EFV plasma concentrations associated with these SNPs may result in greater EFV induction of CYP3A4, resulting in increased LNG metabolism and lower LNG exposure in the patients who were heterozygous or homozygous for CYP2B6 516G>T or CYP2B6 15582C>T.	Genotype CT is associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype CC.	28187506	1448684682
CYP2B6	CYP2B61, CYP2B69	*9	clopidogrel	efficacy	no	in Turkish patients who underwent percutaneous coronary interventions with stent implantation. Patients with PRU values >208 were classified as non-responsiveness to clopidogrel therapy.	CYP2B6 9 is not associated with response to clopidogrel as compared to CYP2B6 1/*1.	28135763	1448633778
CYP2B6	CYP2B61, CYP2B66	6/6 + 1/6	efavirenz	metabolism/PK	yes	"Significantly elevated levels (t-test) were found for 1/6 heterozygotes (58.9 ug h/ ml, P=0.01; N=41) and 186.4 ug h/ml for 6/6 homozygotes(P<0.0001; N=17)".	CYP2B6 6/6 + 1/6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	17235330	1448995983
CYP2B6	CYP2B61, CYP2B64	1/4	efavirenz	metabolism/PK	yes		CYP2B6 1/4 are associated with decreased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	17235330	1448996001
CYP2B6	CYP2B61, CYP2B622	1/22	efavirenz	metabolism/PK	no		CYP2B6 1/22 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	17235330	1448996021
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.	18728241	1448995933
CYP2B6	rs28399499	CC + CT	efavirenz	metabolism/PK	yes		Genotypes CC + CT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype TT.	25889207	1448997158
CYP2B6	rs3181842	CC + CT	efavirenz	metabolism/PK	yes	"For rs3181842, an increase in CYP2B6 activity was observed between volunteers with T/T versus T/C (31.9% increase; p<0.05) and C/C genotypes (70.6% increase; p<0.0001)".	Genotypes CC + CT are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype TT.	28960269	1448997596
CYP2B6	rs3745274	TT	nevirapine	metabolism/PK	yes		Genotype TT is associated with increased concentrations of nevirapine in people with HIV Infections as compared to genotypes GG + GT.	19218571	1448993707
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	efavirenz	metabolism/PK	yes		CYP2B6 1/6 + 6/6 are associated with increased concentrations of efavirenz in people with HIV as compared to CYP2B6 1/1.	21896912	1448994017
CYP2B6	rs3211371	C	cyclophosphamide	efficacy	no		Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	29938344	1449576817
CYP2B6	rs2279343	AG + GG	cyclophosphamide	efficacy	yes		Genotypes AG + GG are associated with decreased response to cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to genotype AA.	28181240	1449157431
CYP2B6	rs3745274	T	tacrolimus	metabolism/PK	no	No significant difference in dose-adjusted trough concentrations was seen between the GG, GT or TT genotypes at day 3, weeks 1, 2, 3, 4, months 2, 3, 4, 6 or 1 year post-transplant when considering either the DONOR or RECIPIENT genotype.	Allele T is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to allele G.	29454235	1449747856
CYP2B6	CYP2B61, CYP2B66	6/6	bupropion	metabolism/PK	yes	Carriers of CYP2B66/6 had lower hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances. Carriers of CYP2B61/6 did not differ statistically as compared to 1/1.	CYP2B6 6/6 is associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 1/1.	29756345	1449564017
CYP2B6	CYP2B61, CYP2B64, CYP2B6*6	1/4 + 4/6	bupropion	metabolism/PK	yes	Carriers of CYP2B64 allele had increased hydroxylation of both bupropion enantiomers, assessed by plasma hydroxybupropion/bupropion AUC ratios and urine hydroxybupropion formation clearances. "Median hydroxybupropion/bupropion AUC ratios in CYP2B64/X and CYP2B61/1 subjects were 53 (36, 71) and 21 (15, 25) for R,R-hydroxybupropion, 3.4 (2.7, 4.7) and 2.1 (1.6, 2.7) for S,S-hydroxybupropion, and 37 (24, 52) and 15 (10, 18) for total hydroxybupropion."	CYP2B6 1/4 + 4/6 are associated with increased metabolism of bupropion in healthy individuals as compared to CYP2B6 1/1.	29756345	1449564030
CYP2B6	rs2279344	A		metabolism/PK	no		Allele A is not associated with concentrations of (S)-EDDP as compared to allele G.	28184434	1449171089
CYP2B6	rs3211371	TT	methadone	metabolism/PK	yes		Genotype TT is associated with increased concentrations of methadone as compared to genotypes CC + CT.	28184434	1449171049
CYP2B6	rs2279344	A	methadone	metabolism/PK	no		Allele A is not associated with concentrations of methadone as compared to allele G.	28184434	1449171064
CYP2B6	rs8192719	T		metabolism/PK	no		Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	28184434	1449171109
CYP2B6	rs3211371	T		metabolism/PK	no		Allele T is not associated with concentrations of (S)-EDDP as compared to allele C.	28184434	1449171094
CYP2B6	CYP2B61, CYP2B66	6/6		metabolism/PK	yes	Patients with the 6/6 genotype had significantly higher trough plasma levels of (S)-methadone and a trend towards higher trough plasma levels of (R)-methadone (p=0.07)	CYP2B6 6/6 is associated with increased concentrations of s-methadone in people with Opioid-Related Disorders as compared to CYP2B6 1/1 + 1/6.	17178267	1449266547
CYP2B6	CYP2B6 poor metabolizer		buprenorphine	efficacy	no	Response defined by changes in the rate of dropout from treatment between metabolizer phenotypes. Study genotyped for the CYP2B6 1, 4, 6 and 9 alleles and then assigned metabolizer phenotypes.	CYP2B6 poor metabolizer is not associated with response to buprenorphine or methadone in people with Opioid-Related Disorders as compared to CYP2B6 intermediate metabolizer and normal metabolizer.	29333880	1449271192
CYP2B6	rs4802101	C	cyclophosphamide	efficacy	no		Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	29938344	1449576812
CYP2B6	rs8192709	C	cyclophosphamide	efficacy	no		Allele C is not associated with response to cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele T.	29938344	1449576822
CYP2B6	CYP2B61, CYP2B629	1/29	cyclophosphamide	metabolism/PK	yes	For patients with CYP2B61/29, AUC4-OH-CPA(8.95 µmol·h/L) was significantly lower than that for CYP2B61/1 (13.10 µmol·h/L).	CYP2B6 1/29 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 1/1.	28181240	1449157351
CYP2B6	CYP2B61, CYP2B630	1/30	cyclophosphamide	metabolism/PK	yes		CYP2B6 1/30 is associated with decreased metabolism of cyclophosphamide in people with Lymphoma, Non-Hodgkin as compared to CYP2B6 1/1.	28181240	1449157340
CYP2B6	rs4803419	T	methadone	metabolism/PK	no		Allele T is not associated with concentrations of methadone as compared to allele C.	28184434	1449171074
CYP2B6	rs8192709	T	methadone	metabolism/PK	no		Allele T is not associated with concentrations of methadone as compared to allele C.	28184434	1449171079
CYP2B6	CYP2B61, CYP2B62	*2	efavirenz	metabolism/PK	no		CYP2B6 2 is not associated with concentrations of efavirenz in people with HIV as compared to CYP2B6 1/*1.	21896912	1449157016
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	bupropion	metabolism/PK	yes	Subjects carrying the CYP2B66 allele had significantly increased AUCs if bupropion compared to 1/*1 subjects.	CYP2B6 1/6 + 6/6 are associated with decreased metabolism of bupropion in healthy individuals as compared to CYP2B6 1/1.	23840296	1450820343
CYP2B6	rs3745274	GT + TT		metabolism/PK	yes	Significance was lost following multivariate analysis.	Genotypes GT + TT are associated with increased concentrations of (S)-methadone in people with Opioid-Related Disorders as compared to genotype GG.	30907440	1450374121
CYP2B6	rs3745274	G	methadone	dosage	no		Allele G is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele T.	30907440	1450374150
CYP2B6	CYP2B61, CYP2B66	1/6	cotinine	metabolism/PK	yes	Finding was significant across the total study cohort and in a subset of CYP2A6 "decreased metabolizers" (i.e. participants carrying at least one copy of the CYP2A62, 4, 7, 9 or *12 alelles) but lost significance in the subset of CYP2A6 normal metabolizers.	CYP2B6 1/6 is associated with increased clearance of cotinine and nicotine in healthy individuals as compared to CYP2B6 1/1.	18004205	1450811499
CYP2B6	CYP2B61, CYP2B66	1/6 + 6/6	bupropion	efficacy	yes	There was a significant increase in abstinence from smoking in patients carrying at least one 6 allele at the end of bupropion treatment as compared to 6 carriers receiving placebo. By contrast, bupropion did not have a significant effect on abstinence rates over placebo in patients with the 1/1 genotype.	CYP2B6 1/6 + 6/6 are associated with increased response to bupropion in people with Tobacco Use Disorder as compared to CYP2B6 1/1.	17223085	1450811368
CYP2B6	rs8109525	GG	bupropion	efficacy	yes	Patients with the GG genotypes were more likely to have quit smoking in weeks 9-12 of varenicline treatment and at 52 weeks of follow-up.	Genotype GG is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AA + AG.	22048466	1450813804
CYP2B6	CYP2B61, CYP2B611	*11	efavirenz	metabolism/PK	not stated		CYP2B6 11 is associated with increased trough concentration of efavirenz in people with HIV and Tuberculosis as compared to CYP2B6 1.	27045425	1447984382
CYP2B6	CYP2B61, CYP2B66	6/6	lumefantrine	metabolism/PK	no	No significant difference in in metabolic ratio or any other PK parameters assessed between the genotype groups.	CYP2B6 6/6 is not associated with metabolism of lumefantrine in healthy individuals as compared to CYP2B6 1/1.	31549442	1451123305
CYP2B6	CYP2B61, CYP2B66	6/6	artemether	metabolism/PK	yes	Subjects with the 6/6 genotype had a significantly increased metabolic ratio of artemether:dihydroatmemisnin copmared to subjects with the 1/1 genotype. However, there were no significant differences in any other PK parameters assessed.	CYP2B6 6/6 is associated with decreased metabolism of artemether in healthy individuals as compared to CYP2B6 1/1.	31549442	1451123300
CYP2B6	rs3745274	GG + GT	imatinib	efficacy	yes	Increased complete cytogenetic response.	Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.	24293093	1184514346
CYP2B6	rs3745274	GG + TT	imatinib	efficacy	yes	Increased risk of developing cytogenetic resistance to imatinib.	Genotypes GG + TT is associated with increased resistance to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GT.	24293093	1184514375
CYP2B6	rs3745274	TT	efavirenz	"dosage","metabolism/PK"	not stated	In 31 patients dose was reduced from the 600mg/day standard (mainly due to elevated levels of the drug in the presence of significant adverse events). All patients requiring a dose reduction to 200mg/day had the TT genotype.	Genotype TT is associated with decreased dose of efavirenz in people with HIV Infections.	24956253	1184987905
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes		Genotype TT is associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotypes GG + GT.	19531981	1448997489
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	not stated		Genotypes GT + TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	19433561	1448997496
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	16495778	1448997777
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	26107645	1448997129
CYP2B6	rs707265	AA + AG	efavirenz	metabolism/PK	yes	"An increase in CYP2B6 activity was also seen among volunteers carrying the variant allele G/G vs. G/A [34.2% increase; p<0.05] and A/A [72.4% increase; p<0.0001]".	Genotypes AA + AG are associated with increased metabolism of efavirenz in healthy individuals as compared to genotype GG.	28960269	1448997609
CYP2B6	rs2279343	A	methadone	dosage	no	Methadone maintenance dose was not associated with genotype of the SNP but it was correlated to the highest dose ever used. Multiple doses versus single dose, body weight, history of cocaine dependence and ethnicity (Asian>Caucasian>African) were independently associated with methadone dose in multiple regression analysis.	Allele A is not associated with dose of methadone in people with Opioid-Related Disorders as compared to allele G.	25556837	1444695457
CYP2B6	rs1042389	C	efavirenz	efficacy	no		Allele C is not associated with response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype TT.	22951632	1448993544
CYP2B6	rs2279343	GG	efavirenz	metabolism/PK	yes	As shown by increased plasma concentrations (units = mg/L) for those with the GG genotype compared to those with the AG genotype. Fasting plasma efavirenz concentrations were measured 12 hours after the last dose, and after 12 weeks of treatment.	Genotype GG is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype AG.	23254426	1183491434
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	yes	Significantly higher mid-dose EFV plasma concentrations at 12 weeks were seen in patients with the GT genotype compared to patients with the GG genotype.	Genotype GT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	23399569	1184473245
CYP2B6	rs2279343	AA	bupropion	efficacy	yes	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide). 48.0 % of patients with CYP2B6 rs2279343 AA genotype in the bupropion only group succeeded in ceasing smoking compared with 35.5 % of patients carrying the AG or GG genotypes (CYP2B6*4) (35.5 %).	Genotype AA is associated with increased response to bupropion in people with Tobacco Use Disorder as compared to genotypes AG + GG.	26153084	1446765735
CYP2B6	rs2279343	AA	bupropion	efficacy	no	Cessation success required patients to complete 6 months of smoking abstinence confirmed by end-expiratory exhaled carbon monoxide. There was no difference in success rate between genotype groups when looking at all patients regardless of group, patients in the varenicline only group, or the varenicline plus bupropion group.	Genotype AA is not associated with response to bupropion and varenicline in people with Tobacco Use Disorder as compared to genotypes AG + GG.	26153084	1446765748
CYP2B6	rs3745274	GG + TT	imatinib	efficacy	no	Those with the GG or TT genotype had an increased risk of losing their hematologic response to imatinib, as compared to those with the GT genotype. Note that this p-value was not significant.	Genotypes GG + TT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GT.	24293093	1184514388
CYP2B6	rs2279345	C	efavirenz	metabolism/PK	yes	Multivariate analysis of efavirenz plasma levels at weeks 12 and 24 of treatment showed that this SNP significantly contributed (the C allele was associated with decreased efavirenz plasma concentrations).	Allele C is associated with increased metabolism of efavirenz in people with HIV Infections as compared to allele T.	24492364	1184467314
CYP2B6	rs3211371	TT	efavirenz	metabolism/PK	no	Efavirenz plasma concentrations were not significantly different between the CC genotype and CT or the CC genotype and the TT genotype. The T allele was at a significantly lower frequency in Black and Asian patients compared to Caucasian patients.	Genotype TT is not associated with metabolism of efavirenz in people with HIV Infections as compared to genotype CC.	16433869	1184512390
CYP2B6	rs2279345	CT	efavirenz	metabolism/PK	yes	Significantly lower efavirenz plasma levels were observed in patients with the CT genotype compared to TT only at 24 weeks (after rifampin discontinuation). All patients had the CYP2B61/1 haplotype (as determined by 7 SNPs) before being assessed by this SNP. Please note; this SNP was described as 18492T>C (and previous studies by this group provided the rsID).	Genotype CT is associated with increased metabolism of efavirenz in people with HIV Infections as compared to genotype TT.	24492364	1184467305
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	CYP2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk, and infant plasma.	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	25882300	1448997209
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	As determined by higher efavirenz plasma concentration. Was significant in univariate analysis (did not report results for multivariate analysis). In particular, two outliers with the TT genotype had very high concentrations.	Genotypes GT + TT is associated with decreased metabolism of efavirenz in people with HIV Infections as compared to genotype GG.	20625352	1184349348
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	Patients with the TT genotype had higher plasma efavirenz concentrations compared to patients with the GG genotype: 2.50 mg/L [0.98-10.00] for GG genotype vs 8.78 mg/L [4.77-10.00] for TT genotype; P=0.005.	Genotype TT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GT.	24551111	1184472014
CYP2B6	rs3745274	TT	efavirenz	metabolism/PK	yes	CYP2B6*6 TT had 63% lower CL/F (CV=9%).	Genotype TT are associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	25889207	1448997148
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	yes	Patients with the GT genotype had higher plasma efavirenz concentrations compared to patients with the GG genotype: 2.50 mg/L [0.98-10.00] for GG genotype vs 3.47 mg/L [1.35-8.73] for GT genotype.	Genotype GT is associated with decreased clearance of efavirenz in people with HIV Infections as compared to genotype GG.	24551111	1184233832
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	Multivariate analysis showed that this SNP contributed significantly to variability of efavirenz plasma concentrations: CYP2A6 1093C>T (rs28399454), CYP2B6 516G>T (rs3745274), CYP2B6 983T>C (rs28399499) contributed 27%, 43%, and 29% of the total variance in efavirenz plasma levels, respectively.	Allele T is associated with metabolism of efavirenz in people with HIV Infections as compared to allele G.	24316028	1184473161
CYP2B6	rs3745274	T	efavirenz	metabolism/PK	yes	The T allele was considered a high efavirenz plasma concentration-associated allele, along with rs2307424 allele C, and both were statistically significant predictors of efavirenz plasma concentrations in multivariate stepwise linear regression analysis.	Allele T is associated with decreased metabolism of efavirenz in people with HIV Infections.	23172109	1184473321
CYP2B6	rs3745274	GG	efavirenz	dosage	not stated	This study provided efavirenz dosing advice for patients based on rs3745274 genotype.	Genotype GG is associated with increased dose of efavirenz in people with HIV Infections as compared to genotypes GT + TT.	26196596	1448107499
CYP2B6	rs3745274	GT + TT	efavirenz	efficacy	yes	CYPB2B6 516 T-allele was protective against late virologic failure in patients with initial (6 month) HIV RNA suppression on EFV-based ART.	Genotypes GT + TT are associated with decreased resistance to efavirenz in people with HIV Infections as compared to genotype GG.	28481785	1448617505
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	"The median efavirenz plasma concentration (MEPC) was 2.2 mg/L [interquartile range (IQR) 1.7-2.8 mg/L] and was significantly higher in patients with the deficient CYP2B6 516T."	Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	28145050	1448633511
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	not stated		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	15825040	1448998426
CYP2B6	rs3745274	GT	efavirenz	metabolism/PK	not stated		Genotype GT is associated with increased concentrations of efavirenz in men with HIV Infections as compared to genotype GG.	16857630	1448998466
CYP2B6	rs3745274	GT + TT	levonorgestrel	metabolism/PK	yes	in patients treated with levonorgestrel implant plus efavirenz. The authors hypothesize that the high EFV plasma concentrations associated with these SNPs may result in greater EFV induction of CYP3A4, resulting in increased LNG metabolism and lower LNG exposure in the patients who were heterozygous or homozygous for CYP2B6 516G>T or CYP2B6 15582C>T.	Genotypes GT + TT are associated with decreased concentrations of levonorgestrel in women with HIV Infections as compared to genotype GG.	28187506	1448684673
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes	in patients treated with levonorgestrel implant plus efavirenz. "C12-14h values were 2.1, 2.6, and 8.7 mg/L in GG, GT, and TT genotype groups, respectively (76% difference between homozygote groups)."	Genotypes GT + TT are associated with increased concentrations of efavirenz in women with HIV Infections as compared to genotype GG.	28187506	1448684688
CYP2B6	rs3745274	T	efavirenz	efficacy	yes	This variant was significantly associated with virologic suppression (OR=3.61, 95% CI 1.16-11.22, p trend=0.03) after adjustment for genetic ancestry PCs.	Allele T is associated with increased response to efavirenz or non-nucleoside reverse transcriptase inhibitors in women with HIV Infections as compared to genotype GG.	22951632	1448993523
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in people with HIV Infections as compared to genotype GG.	24299220	1448997239
CYP2B6	rs3745274	GT + TT	efavirenz	metabolism/PK	yes		Genotypes GT + TT are associated with increased concentrations of efavirenz in children with HIV Infections as compared to genotype GG.	19474465	1448998489